Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - 3D Pharmaceuticals Inc. (NasdaqNM:DDDP)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials
Location
Eagleview Corporate Center
665 Stockton Drive
Exton, PA 19341
Phone: (610) 458-8959
Fax: (610) 458-8249
Email: info@3dp.com
Employees (last reported count): 140
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Employment
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 67%
·Over the last 6 months:
 · 8 insider buys; 259.0K shares (1.8% of insider shares)
·Institutional: 48% (147% of float)
(50 institutions)
·Net Inst. Selling: 975.0K shares (+10.12%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
3-Dimensional Pharmaceuticals, Inc. is a drug discovery company that discovers and develops its own drug candidates, which it generally licenses at the pre-clinical or early clinical stage. The Company is also using its technologies to assist collaborators in discovering drug candidates. To facilitate this process, the Company has developed an integrated set of proprietary technologies, called DiscoverWorks, which accelerate and improve the drug discovery process and capitalize on the opportunities presented by new targets for drugs being revealed from the sequencing of the human genome. The Company's technologies also facilitate drug discovery for well-characterized disease targets that have proven difficult using traditional methods. DiscoverWorks technologies can efficiently assimilate and process vast quantities of data produced from the combination of combinatorial chemistry and high-throughput screening, and can be rapidly and efficiently scaled to meet increasing demand.
More from Market Guide: Expanded Business Description

Financial Summary
DDDP is a drug discovery company that has developed an integrated set of technologies for the cost-effective discovery of small molecule pharmaceuticals. For the six months ended 6/30/01, revenues rose from $3.6 million to $12.4 million. Net loss applicable to Common fell 28% to $4.7 million. Revenues reflect new and continuing collaborations with Bristol-Myers, Centocor and Schering AG. Lower loss reflects an increase in interest income and a decrease in interest expenses.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

James Cavanaugh, Ph.D., 64
Chairman
--  --  
David U'Prichard, Ph.D., 52
CEO, Director
$675K$486K
F. Raymond Salemme, Ph.D., 56
Pres, CSO, Director
395K336K
Wendy Nagy, 58
Sr. VP, Gen. Counsel
--  --  
Roger Bone, Ph.D., 43
Sr. VP of R&D
232K--  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:DDDPAs of 31-Aug-2001
Price and Volume
52-Week Low
on 27-Mar-2001
$7.25 
Recent Price$8.90 
52-Week High
on 1-Sep-2000
$39.938
Daily Volume (3-month avg)43.5K
Daily Volume (10-day avg)19.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y]
52-Week Change-77.1%
52-Week Change
relative to S&P500
-69.3%
Share-Related Items
Market Capitalization$195.4M
Shares Outstanding22.0M
Float7.20M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$4.40 
Earnings (ttm)-$0.32 
Earnings (mrq)-$0.14 
Sales (ttm)$1.00 
Cash (mrq)$4.87 
Valuation Ratios
Price/Book (mrq)2.02 
Price/EarningsN/A 
Price/Sales (ttm)8.89 
Income Statements
Sales (ttm)$21.2M
EBITDA (ttm)-$10.1M
Income available to common (ttm)-$6.73M
Profitability
Profit Margin (ttm)-31.4%
Operating Margin (ttm)-57.8%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-6.33%
Return on Equity (ttm)-9.52%
Financial Strength
Current Ratio (mrq)7.37 
Debt/Equity (mrq)0.02 
Total Cash (mrq)$106.7M
Short Interest
As of 8-Aug-2001
Shares Short15.0K
Percent of Float0.2%
Shares Short
(Prior Month)
16.0K
Short Ratio0.42 
Daily Volume36.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.